
Certara (CERT) Stock Forecast & Price Target
Certara (CERT) Analyst Ratings
Bulls say
Certara is expected to drive strong growth and profitability in the coming quarters due to a combination of factors such as increased production levels (+35% YoY in 2Q26), improved silver recovery rates, and a favorable pricing environment. Additionally, the company has a strong presence in key revenue-generating markets and a diverse portfolio of biosimulation software and technology that helps reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. With its recent court victory, upcoming BFS and PEA for key assets, and a sharp focus on its differentiated MIDD/biosimulation assets, CERT is well-positioned for long-term growth and profitability.
Bears say
Certara is facing several fundamental headwinds, including slower than expected revenue growth, a shift towards project-based business in its QSP segment, struggles in the Asian market, and potential passive selling pressure from small-cap market indexes. These issues, along with limited financial impact from partnerships and a longer-term outlook for new CEO initiatives, suggest that the company may face challenges in increasing profitability and attracting investors. Additionally, the company's ongoing investment in AI and regulatory initiatives may take time to yield results, posing a risk to its near-term financial performance.
This aggregate rating is based on analysts' research of Certara and is not a guaranteed prediction by Public.com or investment advice.
Certara (CERT) Analyst Forecast & Price Prediction
Start investing in Certara (CERT)
Order type
Buy in
Order amount
Est. shares
0 shares